Nasdaq 100 Stocks SEC Filings — September 11, 2026

CPO Cox sold 18,578 shares at $650.21 (~$12.1M) plus 1,422 at $651.15 (~$926K) under a Rule 10b5-1 plan, reducing holdings to 244,516 shares. The sale is pre-scheduled, but the size and timing at near-peak prices suggest insiders are monetizing gains

EVP, CFO & COO Palkhiwala sold 739 shares across 9 transactions (avg ~$179.76), totaling ~$136K, under a Rule 10b5-1 plan. The small size is routine, but the frequency of transactions indicates ongoing diversification

EVP Brosius sold 48 shares total (~$17K) under a Rule 10b5-1 plan at prices between $347.66 and $365.79. The minimal size is immaterial, but the sale at a 5% premium to the first trade suggests a slightly favorable view on valuation

Director List Teri received 42.639 RSUs, and Director Peterson Sandra E received 48.902 RSUs, the largest director awards in the batch, aligning leadership with long-term performance

Director Hoffman Reid received 31.692 RSUs, and Director Pritzker Penny S received 26.838 RSUs, indicating continued board commitment to equity-based compensation

CMO Berger Dietmar exercised 533 RSUs and had 263 shares withheld for taxes (~$38K), a routine transaction that maintains his stake at 19,522 shares, showing no bearish signal

EVP Cain Wettan Keeley M exercised 590 RSUs and had 285 shares withheld for taxes (~$41K), a standard tax-related transaction with no market impact

Director Mason Mark received 0.787 RSUs, a minimal award, but the consistency of director RSU grants across the board signals stable governance

Director Walmsley Emma N received 2.563 RSUs, and Director Rainey John D received 0.778 RSUs, continuing the pattern of routine director compensation

Director MacGregor Catherine received 4.405 RSUs, and Director Johnston Hugh F received 4.341 RSUs, further evidence of systematic RSU awards

Director Di Sibio Carmine received 0.255 RSUs, the smallest award, but still part of the board's compensation cycle

Three Form 4 filings could not be parsed due to EDGAR retrieval issues, limiting visibility into insider activity; this is a data gap rather than a signal

CPO Cox sold ~$13M in stock, the largest insider sale in this batch. While under a 10b5-1 plan, the sale at $650+ per share, near all-time highs, could signal that insiders view the stock as fully valued

CFO Palkhiwala executed 9 separate sales in one day, indicating a systematic liquidation pattern. Although small in value, the frequency suggests a desire to reduce exposure at current levels

EVP Brosius sold shares at $365.79, a 5% premium to his earlier sale at $347.66, indicating a strategic exit at higher prices. The small size limits impact, but the timing is notable

Three Form 4 filings could not be parsed, creating a blind spot for insider activity monitoring. Investors should seek alternative data sources for Gilead insider transactions

Director RSU awards, while small, contribute to ongoing equity dilution. The cumulative effect across 10 directors is minor but should be tracked against share buyback activity

The absence of any open-market insider purchases across all 19 filings suggests a lack of conviction buying, which could be a contrarian bearish signal if sustained

With the stock trading at $650+, the CPO's sale could be a signal that the market is pricing in peak growth, especially if AI-related spending pressures margins

The CFO's 9 transactions in one day may indicate a planned diversification strategy, which could be a negative signal if other executives follow suit

The consistent RSU awards to 10 directors signal a stable board and long-term alignment, supporting a 'hold' thesis for long-term investors

The CPO's sale is pre-scheduled, reducing the negative signal. Investors can view this as a non-event and focus on Meta's AI-driven growth prospects

The CFO's small sales (~$136K) are immaterial relative to his holdings, suggesting no bearish conviction. This could be a buying opportunity if the stock dips on unrelated news

The RSU exercises by CMO and EVP indicate confidence in the company's long-term prospects, as they converted restricted units into common stock, albeit with tax withholding

The minimal selling by EVP Brosius (48 shares) is negligible, and the stock's price strength ($365+) suggests robust demand for surgical robotics, a positive long-term trend

The board's continued equity compensation, including larger awards to List and Peterson, indicates confidence in future performance, which could support a 'buy' thesis

The lack of negative insider activity (no large open-market sales) provides a clean slate for investors to focus on fundamentals, such as upcoming earnings and product launches

3 of 4 companies with insider transactions (Meta, Qualcomm, Intuitive Surgical) show selling, all under 10b5-1 plans, indicating a trend of planned monetization at high valuations across mega-cap tech

Microsoft's 10 director RSU awards and Gilead's RSU exercises are standard governance practices, highlighting the importance of distinguishing between routine and discretionary insider activity

Across all 19 filings, there are zero open-market purchases, suggesting a cautious insider sentiment across the NASDAQ-100, which could be a contrarian indicator if earnings remain strong

3 Gilead filings were unparseable, underscoring the need for robust data infrastructure in monitoring insider activity, especially for large-cap pharma

Insider sales at Meta ($650) and Intuitive Surgical ($365) occur at elevated price levels, suggesting that insiders are taking profits, which may indicate that these stocks are fully valued in the near term

Monitor for additional insider sales by other executives, especially CEO Zuckerberg, and watch for any 10b5-1 plan amendments that could signal a change in sentiment

Watch for further CFO sales and any changes in the 10b5-1 plan; also monitor upcoming earnings for guidance on AI-related revenue growth

Track insider selling patterns and any new 10b5-1 plans; also watch for FDA approvals or product launches that could drive the stock higher

Monitor for any open-market buying by directors or executives, which would be a strong bullish signal; also watch for changes in the RSU award schedule

Seek alternative data sources for insider activity given the EDGAR parsing issues; also monitor for any clinical trial results or regulatory news that could impact the stock

Watch for any Form 144 filings or 10b5-1 plan updates that could indicate upcoming large sales, and monitor insider buying as a contrarian signal